Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 23 April 2009, Vol. 113, No. 17, pp. 4114-4124.
Prepublished online as a Blood First Edition Paper on January 23, 2009; DOI 10.1182/blood-2008-09-177923.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Tables and Figure
Right arrow All Versions of this Article:
blood-2008-09-177923v1
113/17/4114    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Neven, B.
Right arrow Articles by Fischer, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Neven, B.
Right arrow Articles by Fischer, A.
Related Collections
Right arrow Immunobiology
Right arrow Transplantation
Right arrow Clinical Trials and Observations
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

TRANSPLANTATION

Long-term outcome after hematopoietic stem cell transplantation of a single-center cohort of 90 patients with severe combined immunodeficiency

Bénédicte Neven13, Sandrine Leroy1,4, Hélène Decaluwe1, Francoise Le Deist5, Capucine Picard1,3,5,6, Despina Moshous13, Nizar Mahlaoui1,3, Marianne Debré1,3, Jean-Laurent Casanova1,3,6, Liliane Dal Cortivo2,3,7, Yoann Madec8, Salima Hacein-Bey-Abina2,3,7, Geneviève de Saint Basile2,3, Jean-Pierre de Villartay2,3, Stéphane Blanche1,3, Marina Cavazzana-Calvo2,3,7, and Alain Fischer13

1 Unité d'Immuno-Hématologie et Rhumatologie Pédiatrique, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France; 2 Développement Normal et Pathologique du Système Immunitaire, Inserm U768, Hôpital Necker-Enfants Malades, Paris, France; 3 Université Paris-Descartes, Paris, France; 4 Center of Statistics in Medicine, Wolfson College, University of Oxford, Oxford, United Kingdom; 5 Centre d'Étude des Déficits Immunitaires, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France; 6 Laboratoire de Génétique Humaine des Maladies Infectieuses, Inserm U550, Hôpital Necker-Enfants Malades, Université Paris Descartes, Paris, France; 7 Département de Biothérapie, Hôpital Necker-Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France; and 8 Unité d'Épidémiologie des Maladies Émergentes, Institut Pasteur, Paris, France

Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for severe combined immunodeficiency (SCID). Detailed assessment of the long-term outcome of HSCT, ie, the occurrence of clinical events and the quality and stability of immune reconstitution, is now required. We performed a single-center retrospective analysis of the long-term outcome of HSCT in 90-patient cohort followed for between 2 and 34 years (median, 14 years). Clinical events and immune reconstitution data were collected. Almost half the patients have experienced one or more significant clinical events, including persistent chronic graft-versus-host disease (GVHD), autoimmune and inflammatory manifestations, opportunistic and nonopportunistic infections, chronic human papilloma virus (HPV) infections, and a requirement for nutritional support. With the notable exception of severe HPV infection, these complications tend to become less common 15 years later after HSCT. A multivariate analysis showed that the occurrence of these events correlated with non–genoidentical donors, diagnosis of Artemis SCID, and quality of immune reconstitution. In most cases, HSCT enables long-term survival with infrequent sequelae. However, the occurrence of relatively late-onset complications is a concern that requires specific means of prevention and justifies careful patient follow-up.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
F. T. Hakim
TRECing long-term success in SCID
Blood, August 13, 2009; 114(7): 1287 - 1288.
[Full Text] [PDF]


Home page
BloodHome page
M. Sarzotti-Kelsoe, C. M. Win, R. E. Parrott, M. Cooney, B. K. Moser, J. L. Roberts, G. D. Sempowski, and R. H. Buckley
Thymic output, T-cell diversity, and T-cell function in long-term human SCID chimeras
Blood, August 13, 2009; 114(7): 1445 - 1453.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020